Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$18.68
-$0.39(-2.48%)
At close: 4:00 PM EDT
$18.68
-$0.39(-2.48%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume550.01K
Average Volume (3M)933.51K
Market Cap
$1.12B
Enterprise Value$16.79M
Total Cash (Recent Filing)$970.91M
Total Debt (Recent Filing)$20.99M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 10, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding61,136,772
10 Day Avg. Volume817,486
30 Day Avg. Volume933,513
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$34.22Price Target Upside83.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$31.62M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Janux substantial financial flexibility while it funds clinical development and absorbs setbacks. Limited borrowing reduces interest and refinancing pressure, allowing more of its capital base to support research, partnerships, and pipeline advancement over the next several quarters.
Revenue And Gross Margin MomentumStrong trailing revenue growth alongside a healthy gross margin indicates improving partnering or collaboration activity and meaningful economics on reported revenue. If this momentum persists, it can expand funding capacity for the pipeline, although the small revenue base still makes results volatile.
Selective Immuno-oncology PlatformThe platform is designed to activate immune responses more selectively against tumors while limiting activity in healthy tissue. This approach could support a differentiated oncology pipeline and improve therapeutic tolerability if clinical development validates the underlying engineering strategy.
Bears Say
Deep Operating LossesJanux remains far from breakeven, with substantial R&D and operating spending relative to its revenue base. Persistent losses reduce internally generated funding and make future progress dependent on continued financing, collaboration proceeds, or successful advancement of development programs.
Continued Cash BurnNegative operating and free cash flow show that ongoing development consumes significant cash rather than funding itself. Although operating burn improved from 2025, continued outflows and materially negative free cash flow can constrain investment flexibility and increase reliance on external capital.
Clinical-stage Revenue DependenceThe company lacks product sales and depends primarily on partnership-related payments while its programs remain in development. Such revenue is contingent on clinical progress, regulatory approvals, and commercialization outcomes, creating structural uncertainty around the durability and timing of cash inflows.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $1.12B.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 28 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.099.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.47.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 61,136,772 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -1.553%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.22 (83.20% Upside)
$34.22 (83.20% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 368.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.85%
12-Months-Change
Fundamentals
Return on Equity
-10.79%
Trailing 12-Months
Asset Growth
-2.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$34.22
▲(83.20% Upside)
Technical Analysis
Ownership Overview
19.89% Insiders
13.15% Mutual Funds
0.15% Other Institutional Investors
54.17% Public Companies and
Individual Investors